Clinical study on aroprolol hydrochloride combined with sacubitril valsartan sodium in treatment of heart failure
Objective To explore the clinical efficacy of aroprolol hydrochloride combined with sacubi-tril valsartan sodium in the treatment of heart failure.Methods A total of 100 patients with heart failure ad-mitted to the hospital from May 2021 to April 2022 were selected and divided into the group A and the group B according to the random number table method,50 cases in each group.The group A was treated with aro-prolol hydrochloride combined with sacubitril valsartan sodium,and the group B was treated with sacubitril valsartan sodium.The total clinical effective rate,incidence of adverse cardiovascular events and cardiac func-tion indexes[left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),cardi-ac index(CI),stroke volume(SV)],vascular endothelial function indexes[endothelin-1(ET-1),brachial artery endothelium-dependent diastolic function(FMD),nitric oxide(NO),brachial artery endothelium-independent diastolic function(NMD)]were compared between the two groups.Results The total clinical effective rate of-the group A was 96.00％,which was higher than 80.00％of the group B,and the difference was statistically significant(P＜0.05).After treatment,the levels of LVEF,SV,CI,NO,FMD and NMD in the group A were higher than those in the group B,and the levels of LVEDD and ET-1 were lower than those in the group B,the differences were statistically significant(P＜0.05).After treatment,the levels of serum N-terminal pro-B-type natriuretic peptide,hypersensitive C-reactive protein,histone deacetylase 2,and secretory curl related protein 2 in the two groups were significantly different from those before treatment(P＜0.05),and the indexes in the group A were better than those in the group B(P＜0.05).The incidence of adverse cardiovascular events in the group A was lower than that in the group B,the difference was statistically significant(P＜0.05).Conclu-sion Aroprolol hydrochloride combined with sacubitril valsartan sodium is effective in the treatment of heart failure,which can effectively improve cardiac function,reduce vascular endothelial function damage,promote disease recovery,and reduce the incidence of adverse cardiovascular events.
万方数据
维普
